Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure | Quddus et al. Journal of Hematology Oncology 2010 3 16 http www.jhoonline.Org content 3 1 16 JOURNAL OF HEMATOLOGY ONCOLOGY CASE REPORT Open Access OralEzatiostat HCl TLK199 and Myelodysplastic syndrome A case report of sustained hematologic response following an abbreviated exposure Fahd Quddus1 Jessica Clima2 Helen Seedham2 Ghulam Sajjad2 Naomi Galili2 and Azra Raza 2 Abstract Treatment options for patients with lower risk non-del 5q myelodysplastic syndromes MDS who fail erythroid stimulating agents are restricted to one of the hypomethylating drugs with an expected response rate of 50 . Ezatiostat HCl an agent with the potential for producing multi-lineage responses in this population is currently in clinical investigation phase. This case report describes a 77 year old male who received less than two cycles of therapy with ezatiostat HCl which had to be aborted due to intolerable side effects but which produced a sustained normalization of all three blood counts. This trilineage response has now lasted for more than a year. Interestingly the patient began with a del 5q abnormality and responded briefly to lenalidomide. Upon relapse of the anemia a bone marrow showed the disappearance of the del 5q but the appearance of a new clonal abnormality t 2 3 . Given that the patient had a complete cytogenetic response to a truncated exposure to lenalidomide followed by a trilineage response to an even briefer course of ezatiostat HCl suggests a potential role for ezatiostat HCl in del 5q patients who relapse following lenalidomide. Background Myelodysplastic syndromes MDS are a group of bone marrow stem cell disorders which generally affect the elderly median age of 70 years and present with the paradox of a variable cytopenia with a cellular marrow. Prog-nostically these syndromes are broadly divided into those having a lower or higher risk of transformation to acute myeloid leukemia AML on the basis of three variables the number of cytopenias percentage of bone .
